STOCK TITAN

Cingulate (CING) Stock News, Jun-Sep 2023

CING NASDAQ

Cingulate Inc. reports clinical, regulatory, intellectual property and financing developments tied to its Precision Timed Release™ drug-delivery platform. The clinical-stage biopharmaceutical company is focused on once-daily, multi-core tablet formulations for central nervous system conditions, led by CTx-1301 (dexmethylphenidate HCl) for attention deficit/hyperactivity disorder.

Company news commonly covers CTx-1301 data presentations, FDA interactions under the 505(b)(2) pathway, patent activity in the United States and Europe, commercial supply and launch-preparation arrangements, quarterly financial results, private placements, at-the-market financing capacity, and governance or executive updates.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.34%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.00%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags

FAQ

What is the current stock price of Cingulate (CING)?

Cingulate (CING) last closed at $5.11.

What is the market cap of Cingulate (CING)?

The market cap of Cingulate (CING) is approximately $76.5M.